Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors

被引:13
作者
Al Thani, Najlaa A. [1 ]
Hasan, Maram [2 ]
Yalcin, Huseyin C. [2 ,3 ]
机构
[1] Barzan Holdings, Res & Dev Dept, POB 7178, Doha, Qatar
[2] Qatar Univ, Biomed Res Ctr, POB 2713, Doha, Qatar
[3] Qatar Univ, QU Hlth, Coll Hlth Sci, Dept Biomed Sci, POB 2713, Doha, Qatar
关键词
SLGT2; Diabetes; Heart failure; Cardioprotection; Gliflozins; Empagliflozin; Canagliflozin; Animal models; NONDIABETIC HEART-FAILURE; RODENT MODELS; PIG; EMPAGLIFLOZIN; ATHEROSCLEROSIS; ZEBRAFISH; DEFICIENCY; NUTRITION; PRESSURE; TARGET;
D O I
10.1007/s12265-023-10379-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent one type of new-generation type 2 diabetes (T2DM) drug treatment. The mechanism of action of an SGLT2 inhibitor (SGLT2i) in treating T2DM depends on lowering blood glucose levels effectively via increasing the glomerular excretion of glucose. A good number of randomized clinical trials revealed that SGLT2is significantly prevented heart failure (HF) and cardiovascular death in T2DM patients. Despite ongoing clinical trials in HF patients without T2DM, there have been a limited number of translational studies on the cardioprotective properties of SGLT2is. As the cellular mechanism behind the cardiac benefits of SGLT2is is still to be elucidated, animal models are used to better understand the pathways behind the cardioprotective mechanism of SGLT2i. In this review, we summarize the animal models constructed to study the cardioprotective mechanisms of SGLT2is to help deliver a more comprehensive understanding of the in vivo work that has been done in this field and to help select the most optimal animal model to use when studying the different cardioprotective effects of SGLT2is.
引用
收藏
页码:975 / 986
页数:12
相关论文
共 80 条
  • [1] AMENDE I, 1992, J CARDIOVASC PHARM, V20, pS42
  • [2] The Failing Heart Relies on Ketone Bodies as a Fuel
    Aubert, Gregory
    Martin, Ola J.
    Horton, Julie L.
    Lai, Ling
    Vega, Rick B.
    Leone, Teresa C.
    Koves, Timothy
    Gardell, Stephen J.
    Krueger, Marcus
    Hoppel, Charles L.
    Lewandowski, E. Douglas
    Crawford, Peter A.
    Muoio, Deborah M.
    Kelly, Daniel P.
    [J]. CIRCULATION, 2016, 133 (08) : 698 - 705
  • [3] Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
    Baartscheer, Antonius
    Schumacher, Cees A.
    Wust, Rob C. I.
    Fiolet, Jan W. T.
    Stienen, Ger J. M.
    Coronel, Ruben
    Zuurbier, Coert J.
    [J]. DIABETOLOGIA, 2017, 60 (03) : 568 - 573
  • [4] Animal models in nutrition research
    Baker, David H.
    [J]. JOURNAL OF NUTRITION, 2008, 138 (02) : 391 - 396
  • [5] Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization
    Baker, Hana E.
    Kiel, Alexander M.
    Luebbe, Samuel T.
    Simon, Blake R.
    Earl, Conner C.
    Regmi, Ajit
    Roell, William C.
    Mather, Kieren J.
    Tune, Johnathan D.
    Goodwill, Adam G.
    [J]. BASIC RESEARCH IN CARDIOLOGY, 2019, 114 (03)
  • [6] SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
    Banerjee, Sanjay K.
    McGaffin, Kenneth R.
    Pastor-Soler, Nuria M.
    Ahmad, Ferhaan
    [J]. CARDIOVASCULAR RESEARCH, 2009, 84 (01) : 111 - 118
  • [7] Novel Reversible Model of Atherosclerosis and Regression Using Oligonucleotide Regulation of the LDL Receptor
    Basu, Debapriya
    Hu, Yunying
    Huggins, Lesley-Ann
    Mullick, Adam E.
    Graham, Mark J.
    Wietecha, Tomasz
    Barnhart, Shelley
    Mogul, Allison
    Pfeiffer, Katharina
    Zirlik, Andreas
    Fisher, Edward A.
    Bornfeldt, Karin E.
    Willecke, Florian
    Goldberg, Ira J.
    [J]. CIRCULATION RESEARCH, 2018, 122 (04) : 560 - 567
  • [8] Bers D. M., 2001, ExcitationContraction Coupling and Cardiac Contractile Force
  • [9] Altered cardiac myocyte Ca regulation in heart failure
    Bers, Donald M.
    [J]. PHYSIOLOGY, 2006, 21 : 380 - 387
  • [10] Inhibitor binding mode and allosteric regulation of Na+-glucose symporters
    Bisignano, Paola
    Ghezzi, Chiara
    Jo, Hyunil
    Polizzi, Nicholas F.
    Althoff, Thorsten
    Kalyanaraman, Chakrapani
    Friemann, Rosmarie
    Jacobson, Matthew P.
    Wright, Ernest M.
    Grabe, Michael
    [J]. NATURE COMMUNICATIONS, 2018, 9